Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

Abstract

Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5.

Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies.

Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

Keywords:

• asthma
• benralizumab
• IL-5
• IL-5Rα
• MEDI-563

Acknowledgment

This review was conducted at the University of Texas Medical Branch at Galveston supported in part by grant UL1RR029876 from the National Center for Research Resources, National Institutes of Health. A Ghazi and A Trikha contributed equally to this work.

Notes